A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity
- 1 December 1996
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 95 (3) , 527-530
- https://doi.org/10.1046/j.1365-2141.1996.d01-1932.x
Abstract
We studied the pharmacokinetics and toxicity of 220 mg/m2 melphalan (HDM 220) followed by autologous stem cell transplantation in 16 patients with advanced haematological malignancies. Pharmacokinetic parameters (mean values of steady‐state volume of distribution 14.6 l/m2, total body clearance 313 ml/min/m2, elimination half‐life 46 min) were the same as those of 140 or 200 mg/m2 melphalan in previous reports. HDM 220 was feasible. Extramedullary toxicity was mainly W.H.O. grade 4 mucositis (13/16 patients). The median duration of 41 d (10, not reached) of thrombocytopenia 9/l was long. In multiple myeloma the response rate was 89% in heavily pretreated patients, suggesting that HDM 220 could be considered earlier in the course of the disease as an alternative consolidation therapy.Keywords
This publication has 0 references indexed in Scilit: